Kinter Audrey, McNally Jonathan, Riggin Lindsey, Jackson Robert, Roby Gregg, Fauci Anthony S
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3390-5. doi: 10.1073/pnas.0611423104. Epub 2007 Feb 21.
CD25(+) CD4(+) FoxP3(+) regulatory T (Treg) cells isolated from the peripheral blood of asymptomatic HIV-infected individuals have been demonstrated to significantly suppress HIV-specific immune responses in vitro. CD25(+) Treg cell suppressor activity in the peripheral blood seems to diminish with progression of HIV disease, and it has been suggested that loss of Treg cells contributes to aberrant immune activation and disease progression. However, phenotypic studies suggest that Treg cells may migrate to, and be maintained or even expanded in, tissue sites of HIV replication. Currently, it is not known whether tissue-associated Treg cells maintain suppressive activity in the context of HIV infection, particularly in individuals with advanced disease. The present study demonstrates that CD25(+) Treg cells isolated from lymph nodes and peripheral blood of HIV(+) subjects, even those with high viral loads and/or low CD4(+) T cell counts, maintain potent suppressive activity against HIV-specific cytolytic T cell function. This activity was better in lymph node as compared with peripheral blood, particularly in patients with high levels of plasma viremia. In addition, the expression of certain CD25(+) Treg-associated markers on CD4(+) T cells isolated from lymph nodes differed significantly from those on CD4(+) T cell subsets isolated from the peripheral blood. These data suggest that CD25(+) Treg cell-mediated suppression of HIV-specific responses continues throughout the course of HIV disease and, because of their particularly potent suppression of HIV-specific CTL activity in lymphoid tissue, may considerably impact the ability to control HIV replication in vivo.
从无症状HIV感染者外周血中分离出的CD25(+) CD4(+) FoxP3(+)调节性T(Treg)细胞已被证明在体外能显著抑制HIV特异性免疫反应。外周血中CD25(+) Treg细胞的抑制活性似乎随着HIV疾病的进展而减弱,有人提出Treg细胞的丧失会导致异常免疫激活和疾病进展。然而,表型研究表明,Treg细胞可能迁移至HIV复制的组织部位,并在其中维持甚至扩增。目前尚不清楚在HIV感染的情况下,尤其是在疾病晚期的个体中,组织相关的Treg细胞是否保持抑制活性。本研究表明,从HIV(+)受试者的淋巴结和外周血中分离出的CD25(+) Treg细胞,即使是那些病毒载量高和/或CD4(+) T细胞计数低的个体,对HIV特异性细胞溶解T细胞功能仍保持强大的抑制活性。与外周血相比,这种活性在淋巴结中更强,尤其是在血浆病毒血症水平高的患者中。此外,从淋巴结分离出的CD4(+) T细胞上某些与CD25(+) Treg相关的标志物的表达与从外周血分离出的CD4(+) T细胞亚群上的表达有显著差异。这些数据表明,CD25(+) Treg细胞介导的对HIV特异性反应的抑制在HIV疾病过程中持续存在,并且由于它们对淋巴组织中HIV特异性CTL活性的特别强大的抑制作用,可能会对体内控制HIV复制的能力产生相当大的影响。